Leaf Huang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1261467/publications.pdf

Version: 2024-02-01

267 papers	28,652 citations	2975 93 h-index	5829 161 g-index
281 all docs	281 docs citations	281 times ranked	26196 citing authors

#	Article	IF	Citations
1	A Minimalist Binary Vaccine Carrier for Personalized Postoperative Cancer Vaccine Therapy. Advanced Materials, 2022, 34, e2109254.	21.0	44
2	Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. Journal of Nanobiotechnology, 2022, 20, 9.	9.1	40
3	Magnolol-loaded cholesteryl biguanide conjugate hydrochloride nanoparticles for triple-negative breast cancer therapy. International Journal of Pharmaceutics, 2022, 615, 121509.	5.2	8
4	Nano-trapping CXCL13 reduces regulatory B cells in tumor microenvironment and inhibits tumor growth. Journal of Controlled Release, 2022, 343, 303-313.	9.9	11
5	A PET-based fluorescent probe for monitoring labile Fe(<scp>ii</scp>) pools in macrophage activations and ferroptosis. Chemical Communications, 2022, 58, 2979-2982.	4.1	13
6	Methylglyoxal produced by tumor cells through formaldehyde-enhanced Warburg effect potentiated polarization of tumor-associated macrophages. Toxicology and Applied Pharmacology, 2022, 438, 115910.	2.8	5
7	Strategies targeting tumor immune and stromal microenvironment and their clinical relevance. Advanced Drug Delivery Reviews, 2022, 183, 114137.	13.7	28
8	An anthracenecarboximide-guanidine fluorescent probe for selective detection of glyoxals under weak acidic conditions. RSC Advances, 2022, 12, 9473-9477.	3.6	1
9	Formulation of two lipid-based membraneâ€“core nanoparticles for FOLFOX combination therapy. Nature Protocols, 2022, 17, 1818-1831.	12.0	10
10	Macrophageâ€Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention. Advanced Functional Materials, 2021, 31, 2006220.	14.9	63
11	Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy. Biomaterials, 2021, 269, 120604.	11.4	41
12	Lipid-Coated Cisplatin Nanoparticles for Insoluble Drug Loading. Biomaterial Engineering, 2021, , 97-109.	0.2	1
13	Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis. Nature Nanotechnology, 2021, 16, 466-477.	31.5	72
14	Preparation and Characterization of siRNA-Loaded Liposomes. Methods in Molecular Biology, 2021, 2282, 159-169.	0.9	4
15	Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer. Nanoscale Horizons, 2021, 6, 319-329.	8.0	39
16	Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy. Science Advances, 2021, 7, .	10.3	23
17	mRNA vaccine for cancer immunotherapy. Molecular Cancer, 2021, 20, 41.	19.2	445
18	Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect. Journal of Personalized Medicine, 2021, 11, 124.	2.5	68

#	Article	IF	Citations
19	Tinagl1 Gene Therapy Suppresses Growth and Remodels the Microenvironment of Triple Negative Breast Cancer. Molecular Pharmaceutics, 2021, 18, 2032-2038.	4.6	3
20	Myricetin protects natural killer cells from arsenite induced DNA damage by attenuating oxidative stress and retaining poly(ADP-Ribose) polymerase 1 activity. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2021, 865, 503337.	1.7	1
21	Manipulating Liver Bile Acid Signaling by Nanodelivery of Bile Acid Receptor Modulators for Liver Cancer Immunotherapy. Nano Letters, 2021, 21, 6781-6791.	9.1	15
22	The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1. Science Advances, 2021, 7, eabg9241.	10.3	25
23	Novel Pyropheophorbide Phosphatydic Acids Photosensitizer Combined EGFR siRNA Gene Therapy for Head and Neck Cancer Treatment. Pharmaceutics, 2021, 13, 1435.	4.5	6
24	Therapeutic and delivery strategies of phytoconstituents for renal fibrosis. Advanced Drug Delivery Reviews, 2021, 177, 113911.	13.7	15
25	Arsenite and monomethylarsonous acid disrupt erythropoiesis through combined effects on differentiation and survival pathways in early erythroid progenitors. Toxicology Letters, 2021, 350, 111-120.	0.8	6
26	Formaldehyde reinforces pro-inflammatory responses of macrophages through induction of glycolysis. Chemosphere, 2021, 282, 131149.	8.2	12
27	Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. Molecular Cancer, 2021, 20, 10.	19.2	70
28	Basic fibroblast growth factor blockade enhances lung cancer cell invasion by activating the AKT/MMPâ€2/VEGF pathway. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 43-50.	2.5	3
29	Relaxin-FOLFOX-IL-12 triple combination therapy engages memory response and achieves long-term survival in colorectal cancer liver metastasis. Journal of Controlled Release, 2020, 319, 213-221.	9.9	19
30	Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. Translational Oncology, 2020, 13, 100856.	3.7	9
31	A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking. Cancer Research, 2020, 80, 4972-4985.	0.9	23
32	Formaldehyde inhibits development of T lymphocytes in mice. Toxicological and Environmental Chemistry, 2020, 102, 473-489.	1.2	3
33	Precise delivery of obeticholic acid via nanoapproach for triggering natural killer T cell-mediated liver cancer immunotherapy. Acta Pharmaceutica Sinica B, 2020, 10, 2171-2182.	12.0	32
34	Oral Metformin and Polymetformin Reprogram Immunosuppressive Microenvironment and Boost Immune Checkpoint Inhibitor Therapy in Colorectal Cancer. Advanced Therapeutics, 2020, 3, 2000168.	3.2	4
35	Inhibition of red blood cell development by arsenic-induced disruption of GATA-1. Scientific Reports, 2020, 10, 19055.	3.3	18
36	Elevation in the counts of IL-35-producing B cells infiltrating into lung tissue in mycobacterial infection is associated with the downregulation of Th1/Th17 and upregulation of Foxp3+Treg. Scientific Reports, 2020, 10, 13212.	3.3	14

#	Article	IF	Citations
37	Fluorophore-Promoted Facile Deprotonation and Exocyclic Five-Membered Ring Cyclization for Selective and Dynamic Tracking of Labile Glyoxals. Analytical Chemistry, 2020, 92, 13829-13838.	6.5	18
38	Tackling TAMs for Cancer Immunotherapy: Itâ€™s Nano Time. Trends in Pharmacological Sciences, 2020, 41, 701-714.	8.7	60
39	Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer. Journal of Controlled Release, 2020, 323, 431-441.	9.9	39
40	Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment. Advanced Drug Delivery Reviews, 2020, 154-155, 245-273.	13.7	29
41	Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer. AAPS Journal, 2020, 22, 88.	4.4	8
42	Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma. ACS Nano, 2020, 14, 4816-4828.	14.6	205
43	Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies. Theranostics, 2020, 10, 3099-3117.	10.0	70
44	Remodeling the fibrotic tumor microenvironment of desmoplastic melanoma to facilitate vaccine immunotherapy. Nanoscale, 2020, 12, 3400-3410.	5.6	24
45	Nano-puerarin regulates tumor microenvironment and facilitates chemo- and immunotherapy in murine triple negative breast cancer model. Biomaterials, 2020, 235, 119769.	11.4	93
46	BTLA-Expressing Dendritic Cells in Patients With Tuberculosis Exhibit Reduced Production of IL-12/IFN-Î± and Increased Production of IL-4 and TGF-Î², Favoring Th2 and Foxp3+ Treg Polarization. Frontiers in Immunology, 2020, 11, 518.	4.8	20
47	Natural products remodel cancer-associated fibroblasts in desmoplastic tumors. Acta Pharmaceutica Sinica B, 2020, 10, 2140-2155.	12.0	32
48	Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis. ACS Nano, 2020, 14, 5075-5089.	14.6	144
49	Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells. Toxicology and Applied Pharmacology, 2020, 396, 115001.	2.8	10
50	Membrane-core nanoparticles for cancer nanomedicine. Advanced Drug Delivery Reviews, 2020, 156, 23-39.	13.7	53
51	Advances in Anti-Tumor Treatments Targeting the CD47/SIRPÎ± Axis. Frontiers in Immunology, 2020, 11, 18.	4.8	235
52	Circular RNA hsa_circ_0001380 in peripheral blood as a potential diagnostic biomarker for active pulmonary tuberculosis. Molecular Medicine Reports, 2020, 21, 1890-1896.	2.4	10
53	Nanomaterial Manipulation of Immune Microenvironment in the Diseased Liver. Advanced Functional Materials, 2019, 29, 1805760.	14.9	13
54	Exploration of supersaturable lacidipine ternary amorphous solid dispersion for enhanced dissolution and in vivo absorption. European Journal of Pharmaceutical Sciences, 2019, 139, 105043.	4.0	26

#	Article	IF	Citations
55	Design of Virus-Mimicking Polyelectrolyte Complexes for Enhanced Oral Insulin Delivery. Journal of Pharmaceutical Sciences, 2019, 108, 3408-3415.	3.3	17
56	Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapy. Nature Communications, 2019, 10, 2993.	12.8	90
57	Inhibiting PI3 kinase-Î³ in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors. Journal of Controlled Release, 2019, 309, 173-180.	9.9	35
58	On the issue of transparency and reproducibility in nanomedicine. Nature Nanotechnology, 2019, 14, 629-635.	31.5	149
59	Nanoformulated Codelivery of Quercetin and Alantolactone Promotes an Antitumor Response through Synergistic Immunogenic Cell Death for Microsatellite-Stable Colorectal Cancer. ACS Nano, 2019, 13, 12511-12524.	14.6	110
60	Locally Trapping the Câ€€ Chemokine Receptor Type 7 by Gene Delivery Nanoparticle Inhibits Lymphatic Metastasis Prior to Tumor Resection. Small, 2019, 15, e1805182.	10.0	25
61	MTB driven B cells producing IL-35 and secreting high level of IL-10 in the patients with active pulmonary tuberculosis. Molecular Immunology, 2019, 112, 175-181.	2.2	22
62	High Co-loading Capacity and Stimuli-Responsive Release Based on Cascade Reaction of Self-Destructive Polymer for Improved Chemo-Photodynamic Therapy. ACS Nano, 2019, 13, 7010-7023.	14.6	116
63	Synergistic effect of Soluplus and hyaluronic acid on the supersaturation maintenance of lovastatin: The facilitated in vitro-in vivo performance and improved physical stability. Carbohydrate Polymers, 2019, 222, 114978.	10.2	14
64	Multifunctional lipid-coated calcium phosphate nanoplatforms for complete inhibition of large triple negative breast cancer via targeted combined therapy. Biomaterials, 2019, 216, 119232.	11.4	27
65	Response to Comment on â€œTrapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasisâ€• Advanced Materials, 2019, 31, e1902569.	21.0	0
66	A naphthalimide-aminal-based pH-sensitive fluorescent donor for lysosome-targeted formaldehyde release and fluorescence turn-on readout. Chemical Communications, 2019, 55, 7053-7056.	4.1	16
67	Biomolecule-assisted green synthesis of nanostructured calcium phosphates and their biomedical applications. Chemical Society Reviews, 2019, 48, 2698-2737.	38.1	131
68	Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy. Cancer Letters, 2019, 448, 31-39.	7.2	55
69	Effective Combined Photodynamic Therapy with Lipid Platinum Chloride Nanoparticles Therapies of Oral Squamous Carcinoma Tumor Inhibition. Journal of Clinical Medicine, 2019, 8, 2112.	2.4	14
70	Nanotechnology intervention of the microbiome for cancer therapy. Nature Nanotechnology, 2019, 14, 1093-1103.	31.5	151
71	RNA Interference-Based Cancer Drugs: The Roadblocks, and the â€œDeliveryâ€•of the Promise. Nucleic Acid Therapeutics, 2019, 29, 61-66.	3.6	27
72	Nanoparticle Delivery of RIG-I Agonist Enables Effective and Safe Adjuvant Therapy in Pancreatic Cancer. Molecular Therapy, 2019, 27, 507-517.	8.2	67

#	Article	IF	Citations
73	Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 647-656.	2.5	21
74	Vasodilator Hydralazine Promotes Nanoparticle Penetration in Advanced Desmoplastic Tumors. ACS Nano, 2019, 13, 1751-1763.	14.6	44
75	Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma. ACS Nano, 2018, 12, 1250-1261.	14.6	76
76	Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. Molecular Therapy, 2018, 26, 45-55.	8.2	240
77	mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma. Molecular Therapy, 2018, 26, 420-434.	8.2	132
78	Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut, 2018, 67, 931-944.	12.1	138
79	Targeted drug delivery to melanoma. Advanced Drug Delivery Reviews, 2018, 127, 208-221.	13.7	99
80	BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. Cancer Immunology, Immunotherapy, 2018, 67, 299-310.	4.2	48
81	Nanoparticle-Mediated RNA Interference for Cancer Therapy. , 2018, , 521-539.		0
82	Analyte Regeneration Fluorescent Probes for Formaldehyde Enabled by Regiospecific Formaldehyde-Induced Intramolecularity. Journal of the American Chemical Society, 2018, 140, 16408-16412.	13.7	60
83	An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. Nature Communications, 2018, 9, 5214.	12.8	66
84	Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy. ACS Nano, 2018, 12, 11740-11755.	14.6	176
85	Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers. ACS Nano, 2018, 12, 9830-9841.	14.6	101
86	Trapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis. Advanced Materials, 2018, 30, e1805007.	21.0	125
87	Minimal uranium accumulation in lymphoid tissues following an oral 60-day uranyl acetate exposure in male and female C57BL/6J mice. PLoS ONE, 2018, 13, e0205211.	2.5	14
88	Functional suppression of macrophages derived from THP-1 cells by environmentally-relevant concentrations of arsenite. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2018, 214, 36-42.	2.6	13
89	Lipid-Coated Cisplatin Nanoparticles for Insoluble Drug Loading. , 2018, , 1-13.		0
90	Monomethylarsonous acid: Induction of DNA damage and oxidative stress in mouse natural killer cells at environmentally-relevant concentrations. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2018, 832-833, 1-6.	1.7	3

#	Article	IF	Citations
91	Nano-delivery of fraxinellone remodels tumor microenvironment and facilitates therapeutic vaccination in desmoplastic melanoma. Theranostics, 2018, 8, 3781-3796.	10.0	73
92	Nanoparticleâ€mediated HMGA1 Silencing Promotes Lymphocyte Infiltration and Boosts Checkpoint Blockade Immunotherapy for Cancer. Advanced Functional Materials, 2018, 28, 1802847.	14.9	29
93	Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma. ACS Nano, 2018, 12, 7812-7825.	14.6	159
94	Toxicity of environmentally-relevant concentrations of arsenic on developing T lymphocyte. Environmental Toxicology and Pharmacology, 2018, 62, 107-113.	4.0	21
95	Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nature Communications, 2018, 9, 2237.	12.8	329
96	Novel liposomal technology applied in esophageal cancer treatment. , 2018, , .		1
97	Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node. Molecular Therapy, 2017, 25, 1665-1675.	8.2	265
98	Dual Functional LipoMET Mediates Envelope-type Nanoparticles to Combinational Oncogene Silencing and Tumor Growth Inhibition. Molecular Therapy, 2017, 25, 1567-1579.	8.2	28
99	Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles. ACS Nano, 2017, 11, 4916-4925.	14.6	218
100	Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy. Frontiers of Chemical Science and Engineering, 2017, 11, 676-684.	4.4	9
101	Nanoformulations for combination or cascade anticancer therapy. Advanced Drug Delivery Reviews, 2017, 115, 3-22.	13.7	145
102	A dosimetric model for the heterogeneous delivery of radioactive nanoparticles In vivo: a feasibility study. Radiation Oncology, 2017, 12, 54.	2.7	1
103	Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis. Vaccine, 2017, 35, 2550-2557.	3.8	59
104	Nanomaterials for cancer immunotherapy. Biomaterials, 2017, 148, 16-30.	11.4	226
105	Preface: Nanoformulations for combination or cascade anticancer therapy. Advanced Drug Delivery Reviews, 2017, 115, 1-2.	13.7	1
106	Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. ACS Nano, 2017, 11, 8690-8706.	14.6	108
107	A melanin-mediated cancer immunotherapy patch. Science Immunology, 2017, 2, .	11.9	300
108	Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival. Biomaterials, 2017, 141, 260-271.	11.4	46

#	Article	IF	Citations
109	Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. Journal of Controlled Release, 2017, 245, 81-94.	9.9	122
110	Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors. Cancer Research, 2017, 77, 719-731.	0.9	169
111	Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy. Theranostics, 2017, 7, 253-269.	10.0	50
112	Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform. Theranostics, 2016, 6, 918-929.	10.0	51
113	Evaluation of Toxicity in Mouse Bone Marrow Progenitor Cells. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2016, 67, 18.9.1-18.9.12.	1.1	7
114	Cancer Therapy: Esteraseâ€Activated Chargeâ€Reversal Polymer for Fibroblastâ€Exempt Cancer Gene Therapy (Adv. Mater. 48/2016). Advanced Materials, 2016, 28, 10578-10578.	21.0	2
115	Sigma receptor-mediated targeted delivery of anti-angiogenic multifunctional nanodrugs for combination tumor therapy. Journal of Controlled Release, 2016, 228, 107-119.	9.9	45
116	Monomethylarsonous acid (MMA⁺³) Inhibits IL-7 Signaling in Mouse Pre-B Cells. Toxicological Sciences, 2016, 149, 289-299.	3.1	20
117	Pieter Cullis: an outstanding lipid biophysicist, drug delivery scientist, educator, and entrepreneur. Journal of Drug Targeting, 2016, 24, 762-764.	4.4	1
118	Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery. ACS Applied Materials & Interfaces, 2016, 8, 24361-24367.	8.0	17
119	The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors. ACS Nano, 2016, 10, 9243-9258.	14.6	161
120	Facile Fabrication of Tumor Redoxâ€Sensitive Nanoassemblies of Smallâ€Molecule Oleate Prodrug as Potent Chemotherapeutic Nanomedicine. Small, 2016, 12, 6353-6362.	10.0	147
121	Self-Assembled Redox Dual-Responsive Prodrug-Nanosystem Formed by Single Thioether-Bridged Paclitaxel-Fatty Acid Conjugate for Cancer Chemotherapy. Nano Letters, 2016, 16, 5401-5408.	9.1	346
122	On the article â€œFindings questioning the involvement of Sigma-1 receptor in the uptake of anisamide-decorated particlesâ€•[J. Control. Release 224 (2016) 229â€“238]. Journal of Controlled Release, 2016, 243, 382-385.	9.9	10
123	Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. Journal of Controlled Release, 2016, 244, 63-73.	9.9	74
124	Local and transient gene expression primes the liver to resist cancer metastasis. Science Translational Medicine, 2016, 8, 364ra153.	12.4	67
125	Esteraseâ€Activated Chargeâ€Reversal Polymer for Fibroblastâ€Exempt Cancer Gene Therapy. Advanced Materials, 2016, 28, 10613-10622.	21.0	189
126	PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery. Nature Communications, 2016, 7, 11822.	12.8	133

#	Article	IF	Citations
127	Multistage Delivery Technologies: Multifunctional, Interdisciplinary Approaches to Nanomedicine. Molecular Therapy, 2016, 24, 849-851.	8.2	11
128	Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach. Cancer Letters, 2016, 379, 32-38.	7.2	41
129	A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. Biomaterials, 2016, 102, 239-248.	11.4	59
130	Cisplatin encapsulated nanoparticle as a therapeutic agent for anticancer treatment. Proceedings of SPIE, 2016, , .	0.8	2
131	Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic. Biomaterials, 2016, 82, 178-193.	11.4	100
132	Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model. Molecular Therapy, 2016, 24, 364-374.	8.2	86
133	Nanoparticle Delivered VEGF-A siRNA Enhances Photodynamic Therapy for Head and Neck Cancer Treatment. Molecular Therapy, 2016, 24, 106-116.	8.2	71
134	S-nitrosation on zinc finger motif of PARP-1 as a mechanism of DNA repair inhibition by arsenite. Oncotarget, 2016, 7, 80482-80492.	1.8	22
135	Tri-peptide cationic lipids for gene delivery. Journal of Materials Chemistry B, 2015, 3, 119-126.	5.8	41
136	Nanoparticle delivery of HIF1Î± siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Cancer Letters, 2015, 359, 65-74.	7.2	111
137	Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. Journal of Controlled Release, 2015, 200, 188-200.	9.9	87
138	Delivery of oligonucleotides with lipid nanoparticles. Advanced Drug Delivery Reviews, 2015, 87, 68-80.	13.7	158
139	Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma. Biomaterials, 2015, 68, 54-66.	11.4	69
140	Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene delivery to breast cancer cells. Journal of Materials Chemistry B, 2015, 3, 6805-6812.	5.8	77
141	Exploring the Tumor Microenvironment with Nanoparticles. Cancer Treatment and Research, 2015, 166, 193-226.	0.5	97
142	Theranostic etoposide phosphate/indium nanoparticles for cancer therapy and imaging. Nanoscale, 2015, 7, 18542-18551.	5.6	16
143	Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. Journal of Controlled Release, 2015, 219, 192-204.	9.9	192
144	Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. Journal of Controlled Release, 2015, 217, 27-41.	9.9	101

#	Article	IF	Citations
145	A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging. Journal of Controlled Release, 2015, 217, 170-182.	9.9	41
146	In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Advanced Drug Delivery Reviews, 2015, 81, 128-141.	13.7	533
147	The Cytochrome P450 Epoxygenase Pathway Regulates the Hepatic Inflammatory Response in Fatty Liver Disease. PLoS ONE, 2014, 9, e110162.	2.5	79
148	Lipid Nanoparticles for Gene Delivery. Advances in Genetics, 2014, 88, 13-36.	1.8	118
149	Lipid-Coated Calcium Phosphate Nanoparticles for Nonviral Gene Therapy. Advances in Genetics, 2014, 88, 205-229.	1.8	18
150	Hepatic RNA interference: delivery by synthetic vectors. Drug Delivery and Translational Research, 2014, 4, 61-73.	5.8	8
151	Nanoparticles containing insoluble drug for cancer therapy. Biotechnology Advances, 2014, 32, 778-788.	11.7	127
152	Composite Nanoparticles for Gene Delivery. Advances in Genetics, 2014, 88, 111-137.	1.8	19
153	Nonviral Vectors. Advances in Genetics, 2014, 88, 1-12.	1.8	28
154	Novel Gemini cationic lipids with carbamate groups for gene delivery. Journal of Materials Chemistry B, 2014, 2, 2920-2928.	5.8	28
155	Nanoparticles with Precise Ratiometric Coâ€Loading and Coâ€Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer. Advanced Functional Materials, 2014, 24, 6601-6611.	14.9	154
156	Lipidâ€“calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases. Biomaterials, 2014, 35, 4688-4698.	11.4	97
157	Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials, 2014, 35, 3027-3034.	11.4	73
158	Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. Journal of Controlled Release, 2014, 182, 90-96.	9.9	105
159	Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. Journal of Controlled Release, 2014, 174, 137-142.	9.9	71
160	Co-delivery of Cisplatin and Rapamycin for Enhanced Anticancer Therapy through Synergistic Effects and Microenvironment Modulation. ACS Nano, 2014, 8, 4996-5009.	14.6	163
161	Nanoparticle-Delivered Transforming Growth Factor-Î² siRNA Enhances Vaccination against Advanced Melanoma by Modifying Tumor Microenvironment. ACS Nano, 2014, 8, 3636-3645.	14.6	253
162	Turning a water and oil insoluble cisplatin derivative into a nanoparticle formulation for cancer therapy. Biomaterials, 2014, 35, 7647-7653.	11.4	22

#	Article	IF	Citations
163	Non-viral nanocarriers for siRNA delivery in breast cancer. Journal of Controlled Release, 2014, 190, 440-450.	9.9	75
164	Strategies on the nuclear-targeted delivery of genes. Journal of Drug Targeting, 2013, 21, 926-939.	4.4	44
165	Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery. Journal of Controlled Release, 2013, 172, 179-189.	9.9	28
166	Intravenous Delivery of siRNA Targeting CD47 Effectively Inhibits Melanoma Tumor Growth and Lung Metastasis. Molecular Therapy, 2013, 21, 1919-1929.	8.2	165
167	Lipid-Coated Cisplatin Nanoparticles Induce Neighboring Effect and Exhibit Enhanced Anticancer Efficacy. ACS Nano, 2013, 7, 9896-9904.	14.6	125
168	Turning an antiviral into an anticancer drug: Nanoparticle delivery of acyclovir monophosphate. Journal of Controlled Release, 2013, 170, 414-420.	9.9	35
169	Targeted delivery of EV peptide to tumor cell cytoplasm using lipid coated calcium carbonate nanoparticles. Cancer Letters, 2013, 334, 311-318.	7.2	57
170	Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials, 2013, 34, 8459-8468.	11.4	79
171	Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. Journal of Controlled Release, 2013, 172, 259-265.	9.9	199
172	Systemic Delivery of Modified mRNA Encoding Herpes Simplex Virus 1 Thymidine Kinase for Targeted Cancer Gene Therapy. Molecular Therapy, 2013, 21, 358-367.	8.2	164
173	Nickel(II) Dithiocarbamate Complexes Containing Sulforhodamine B as Fluorescent Probes for Selective Detection of Nitrogen Dioxide. Journal of the American Chemical Society, 2013, 135, 5312-5315.	13.7	64
174	Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials, 2013, 34, 3447-3458.	11.4	85
175	Codelivery of VEGF siRNA and Gemcitabine Monophosphate in a Single Nanoparticle Formulation for Effective Treatment of NSCLC. Molecular Therapy, 2013, 21, 1559-1569.	8.2	107
176	A Highly Efficient Synthetic Vector: Nonhydrodynamic Delivery of DNA to Hepatocyte Nuclei in Vivo. ACS Nano, 2013, 7, 5376-5384.	14.6	100
177	Biodistribution Studies of Nanoparticles Using Fluorescence Imaging: A Qualitative or Quantitative Method?. Pharmaceutical Research, 2012, 29, 3273-3277.	3.5	86
178	Nanoparticle Delivery of Pooled siRNA for Effective Treatment of Non-Small Cell Lung Caner. Molecular Pharmaceutics, 2012, 9, 2280-2289.	4.6	79
179	Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine, 2012, 30, 2256-2272.	3.8	260
180	Lipid-based vectors for siRNA delivery. Journal of Drug Targeting, 2012, 20, 724-735.	4.4	72

#	Article	IF	Citations
181	Trp2 Peptide Vaccine Adjuvanted with (R)-DOTAP Inhibits Tumor Growth in an Advanced Melanoma Model. Molecular Pharmaceutics, 2012, 9, 261-268.	4.6	44
182	Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Therapeutic Delivery, 2012, 3, 1429-1445.	2.2	38
183	Systemic Delivery of siRNA via LCP Nanoparticle Efficiently Inhibits Lung Metastasis. Molecular Therapy, 2012, 20, 609-615.	8.2	116
184	Recent Advances in Nonviral Vectors for Gene Delivery. Accounts of Chemical Research, 2012, 45, 971-979.	15.6	542
185	In Vivo Gene Delivery by Nonviral Vectors: Overcoming Hurdles?. Molecular Therapy, 2012, 20, 1298-1304.	8.2	314
186	The targeted intracellular delivery of cytochromeÂC protein to tumors using lipid-apolipoprotein nanoparticles. Biomaterials, 2012, 33, 3959-3966.	11.4	117
187	Nanoparticle delivery of a peptide targeting EGFR signaling. Journal of Controlled Release, 2012, 157, 279-286.	9.9	65
188	Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. Journal of Controlled Release, 2012, 158, 108-114.	9.9	279
189	The Suppressive Tumor Microenvironment: A Challenge in Cancer Immunotherapy. Molecular Pharmaceutics, 2011, 8, 635-641.	4.6	155
190	In Vivo Delivery of RNAi with Lipid-Based Nanoparticles. Annual Review of Biomedical Engineering, 2011, 13, 507-530.	12.3	156
191	Cancer Immunotherapy and Nanomedicine. Pharmaceutical Research, 2011, 28, 200-214.	3.5	75
192	Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine. Cancer Immunology, Immunotherapy, 2011, 60, 629-638.	4.2	57
193	Nanoparticles Escaping RES and Endosome: Challenges for siRNA Delivery for Cancer Therapy. Journal of Nanomaterials, 2011, 2011, 1-12.	2.7	129
194	Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. Journal of Controlled Release, 2010, 142, 416-421.	9.9	423
195	Stealth nanoparticles: High density but sheddable PEG is a key for tumor targeting. Journal of Controlled Release, 2010, 145, 178-181.	9.9	475
196	Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Research, 2010, 38, 8348-8356.	14.5	121
197	Nanoparticles Targeted With NGR Motif Deliver c-myc siRNA and Doxorubicin for Anticancer Therapy. Molecular Therapy, 2010, 18, 828-834.	8.2	169
198	Targeted delivery of RNAi therapeutics for cancer therapy. Nanomedicine, 2010, 5, 1483-1486.	3.3	21

#	Article	IF	Citations
199	The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides. Journal of Drug Targeting, 2010, 18, 567-574.	4.4	23
200	Targeted Intracellular Delivery of Antisense Oligonucleotides via Conjugation with Small-Molecule Ligands. Journal of the American Chemical Society, 2010, 132, 8848-8849.	13.7	111
201	Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy. Molecular Therapy, 2010, 18, 1650-1656.	8.2	488
202	Bryostatin-I: A dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine. Cytokine, 2010, 52, 238-244.	3.2	18
203	Multifunctional Nanoparticles Delivering Small Interfering RNA and Doxorubicin Overcome Drug Resistance in Cancer. Journal of Biological Chemistry, 2010, 285, 22639-22650.	3.4	194
204	Targeted Nanoparticles Deliver siRNA to Melanoma. Journal of Investigative Dermatology, 2010, 130, 2790-2798.	0.7	102
205	The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome. International Journal of Pharmaceutics, 2009, 368, 56-62.	5.2	32
206	Lipid-based systemic delivery of siRNA. Advanced Drug Delivery Reviews, 2009, 61, 721-731.	13.7	424
207	Nonviral Methods for siRNA Delivery. Molecular Pharmaceutics, 2009, 6, 651-658.	4.6	215
208	Novel Cationic Lipid That Delivers siRNA and Enhances Therapeutic Effect in Lung Cancer Cells. Molecular Pharmaceutics, 2009, 6, 696-705.	4.6	90
209	Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 2259-2266.	2.6	396
210	A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunology, Immunotherapy, 2008, 57, 517-530.	4.2	112
211	Pharmacokinetics and Biodistribution of Nanoparticles. Molecular Pharmaceutics, 2008, 5, 496-504.	4.6	1,313
212	Induction of Cytotoxic T-Lymphocytes and Antitumor Activity by a Liposomal Lipopeptide Vaccine. Molecular Pharmaceutics, 2008, 5, 464-471.	4.6	61
213	Activity of different phospholipids in attenuating hyperactivity in bladder irritation. BJU International, 2008, 101, 627-632.	2.5	22
214	Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. Journal of Controlled Release, 2008, 126, 77-84.	9.9	141
215	Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. Journal of Controlled Release, 2008, 130, 22-28.	9.9	110
216	Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives. Journal of Controlled Release, 2008, 130, 238-245.	9.9	97

#	Article	IF	Citations
217	An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. Journal of Controlled Release, 2008, 131, 64-69.	9.9	217
218	Tumor-targeted Delivery of siRNA by Self-assembled Nanoparticles. Molecular Therapy, 2008, 16, 163-169.	8.2	303
219	Efficient Oncogene Silencing and Metastasis Inhibition via Systemic Delivery of siRNA. Molecular Therapy, 2008, 16, 942-946.	8.2	183
220	Preparation and Characterization of pH-Sensitive Vesicles Made of Cholesteryl Hemisuccinate. Drug Development and Industrial Pharmacy, 2008, 34, 134-141.	2.0	8
221	Mechanism of adjuvant activity of cationic liposome: Phosphorylation of a MAP kinase, ERK and induction of chemokines. Molecular Immunology, 2007, 44, 3672-3681.	2.2	159
222	Recent Advances in Liposome-Based Nanoparticles for Antigen Delivery. Polymer Reviews, 2007, 47, 329-344.	10.9	36
223	Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: Influence of the synthesis parameters on transfection efficiency. Biomaterials, 2007, 28, 1267-1279.	11.4	247
224	Targeted Delivery of Antisense Oligodeoxynucleotide and Small Interference RNA into Lung Cancer Cells. Molecular Pharmaceutics, 2006, 3, 579-588.	4.6	261
225	Surface-Modified LPD Nanoparticles for Tumor Targeting. Annals of the New York Academy of Sciences, 2006, 1082, 1-8.	3.8	110
226	Immunostimulation of dendritic cells by cationic liposomes. Molecular Membrane Biology, 2006, 23, 385-395.	2.0	155
227	Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: Therapeutic effect against cervical cancer. Cancer Immunology, Immunotherapy, 2005, 54, 1180-1190.	4.2	79
228	Targeted gene delivery: The role of peptide nucleic acid. International Journal of Peptide Research and Therapeutics, 2005, 10, 161-167.	1.9	0
229	Lipid-Protamine-DNA-Mediated Antigen Delivery. Current Drug Delivery, 2005, 2, 401-406.	1.6	29
230	Immunostimulation Mechanism of LPD Nanoparticle as a Vaccine Carrier. Molecular Pharmaceutics, 2005, 2, 22-28.	4.6	88
231	Nonâ€Viral Vector as Vaccine Carrier. Advances in Genetics, 2005, 54, 315-337.	1.8	50
232	Coating of Mannan on LPD Particles Containing HPV E7 Peptide Significantly Enhances Immunity Against HPV-Positive Tumor. Pharmaceutical Research, 2004, 21, 1018-1025.	3.5	46
233	Anisamide-targeted stealth liposomes: A potent carrier for targeting doxorubicin to human prostate cancer cells. International Journal of Cancer, 2004, 112, 693-700.	5.1	244
234	Targeted gene delivery: the role of peptide nucleic acid. International Journal of Peptide Research and Therapeutics, 2003, 10, 161-167.	0.1	1

#	Article	IF	Citations
235	Targeted gene delivery: the role of peptide nucleic acid. International Journal of Peptide Research and Therapeutics, 2003, 10, 161-167.	1.9	2
236	Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. Urology, 2003, 61, 664-670.	1.0	60
237	Intravesical liposome administrationâ€"a novel treatment for hyperactive bladder in the rat. Urology, 2003, 61, 656-663.	1.0	86
238	Lipidâ€"protamineâ€"DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Molecular Therapy, 2003, 7, 640-648.	8.2	65
239	LPD Nanoparticles-Novel Nonviral Vector for Efficient Gene Delivery. , 2002, 69, 073-081.		19
240	Development of non-viral vectors for systemic gene delivery. Journal of Controlled Release, 2002, 78, 259-266.	9.9	280
241	Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunology, Immunotherapy, 2001, 50, 503-514.	4.2	100
242	Systemic production of IL-12 by naked DNA mediated gene transfer: toxicity and attenuation of transgene expressionin vivo. Journal of Gene Medicine, 2001, 3, 384-393.	2.8	34
243	Improving plasmid DNA-mediated liver gene transfer by prolonging its retention in the hepatic vasculature. Journal of Gene Medicine, 2001, 3, 569-576.	2.8	40
244	Improved DNA/emulsion complex stabilized by poly(ethylene glycol) conjugated phospholipid. Pharmaceutical Research, 2001, 18, 1480-1484.	3.5	13
245	Sequential Injection of Cationic Liposome and Plasmid DNA Effectively Transfects the Lung with Minimal Inflammatory Toxicity. Molecular Therapy, 2001, 3, 673-682.	8.2	96
246	Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 276, L796-L804.	2.9	85
247	Liposome Vectors for In Vivo Gene Delivery. Current Protocols in Human Genetics, 1999, 20, Unit 12.8.	3.5	5
248	The Inhibitory Role of CpG Immunostimulatory Motifs in Cationic Lipid Vector-Mediated Transgene Expression in Vivo. Human Gene Therapy, 1999, 10, 2153-2161.	2.7	232
249	Folate-targeted, Anionic Liposome-entrapped Polylysine-condensed DNA for Tumor Cell-specific Gene Transfer. Journal of Biological Chemistry, 1996, 271, 8481-8487.	3.4	376
250	Potentiation of Cationic Liposome-Mediated Gene Delivery by Polycations. Biochemistry, 1996, 35, 1027-1036.	2.5	486
251	Effects of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: implications in liposomal drug delivery. Pharmaceutical Research, 1996, 13, 710-717.	3.5	95
252	The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochimica Et Biophysica Acta - Biomembranes, 1995, 1235, 289-295.	2.6	714

#	Article	IF	Citations
253	Size Homogeneity of a Liposome Preparation is Crucial for Liposome Biodistribution in Vivo. Journal of Liposome Research, 1992, 2, 57-66.	3.3	19
254	Improved Encapsulation of DNA in pH-Sensitive Liposomes for Transfection. Journal of Liposome Research, 1992, 2, 125-139.	3.3	27
255	Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochimica Et Biophysica Acta - Biomembranes, 1992, 1104, 95-101.	2.6	391
256	Effect of cationic cholesterol derivatives on gene transfer and protein kinase C activity. Biochimica Et Biophysica Acta - Biomembranes, 1992, 1111, 239-246.	2.6	217
257	Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Letters, 1991, 284, 263-266.	2.8	351
258	Drug Delivery by Organ-Specific Immunoliposomes. ACS Symposium Series, 1991, , 275-284.	0.5	3
259	Target-Specific Binding of Immunoliposomes in Vivo. Journal of Liposome Research, 1990, 1, 393-406.	3.3	13
260	Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Letters, 1990, 268, 235-237.	2.8	1,819
261	Biotin-Bearing pH-Sensitive Liposomes: High-Affinity Binding to Avidin Layer. Journal of Liposome Research, 1989, 1, 233-244.	3.3	4
262	Enhanced Neutrophil Stimulation by Phorbol Ester Encapsulated in pH-Sensitive Liposomes. Journal of Liposome Research, 1988, 1, 63-79.	3.3	2
263	Immunoliposomes: Preparation, properties, and applications. Medicinal Research Reviews, 1986, 6, 171-195.	10.5	30
264	Transmembrane nature of acetylcholine receptor as evidenced by protease sensitivity. FEBS Letters, 1979, 102, 9-12.	2.8	17
265	Interactions of Phospholipid Vesicles with Murine Lymphocytes. Membrane Biochemistry, 1978, 1, 1-25.	0.6	42
266	Interactions of Phospholipid Vesicles with Murine Lymphocytes. Membrane Biochemistry, 1978, 1, 27-42.	0.6	17
267	Liposome-Based Nanoparticles: Antigen Delivery. , 0, , 4369-4377.		0